L. de Pádua Silva

Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

Krishna Komanduri, Hoang Q. Nguyen, Marcos de Lima, 2010, Cancer.

Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.

U. Popat, M. Qazilbash, Y. Efebera, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation.

E. Shpall, Y. Nieto, U. Popat, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant

M. Munsell, U. Popat, Q. Bashir, 2012, Leukemia & lymphoma.

Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type

E. Shpall, U. Popat, J. Tarrand, 2010, Haematologica.

Unrelated donor transplantation for acute myelogenous leukemia in first remission.

E. Shpall, B. Andersson, U. Popat, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.

B. Andersson, Y. Nieto, M. Qazilbash, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease.

S. Parmar, E. Shpall, P. Cano, 2009, Blood.

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

H. Kantarjian, E. Shpall, J. Cortes, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age.

U. Popat, M. Qazilbash, D. Couriel, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

Hoang Q. Nguyen, T. Braun, P. Thall, 2010, Cancer.